Public Health Agency of Canada
Symbol of the Government of Canada

Share this page

Canadian Tuberculosis Standards 7th Edition

[Previous page] [Table of Contents] [Next page]

Chapter 6 - Treatment of Latent Tuberculosis Infection

Dick Menzies, MD, MSc
Gonzalo G. Alvarez, MD MPH, FRCPC
Kamran Khan, MD MPH, FRCPC

Table of Contents

  1. Key Messages/Points
  2. General Considerations
  3. Risk Factors for Reactivation of Active Disease from LTBI
  4. Indications for Treatment of LTBI
  5. Recommendations for Treatment
  6. Follow-up and Monitoring During LTBI Therapy
  7. Does Treatment of LTBI Create Drug Resistance?
  8. Program Indicators
  9. References

Key Messages/Points

  • Treatment of latent TB Infection (LTBI) can provide important individual and public health benefits - if given to people at high risk of developing active TB. This benefit has been demonstrated only in those with a positive tuberculin skin test (TST).
  • Before treatment of LTBI is started, active disease must be excluded carefully by means of history, physical examination and chest radiography. Sputum samples should be sent for smear and culture, or other appropriate investigations should be performed if active disease is considered possible.
  • The decision to treat LTBI should be individualized, with consideration of the risks of therapy from adverse events, such as hepatotoxicity, balanced against the risk of development of active disease.
  • The current standard for treatment of LTBI is self-administered isoniazid (INH) taken daily for 9 months (9INH), as this shows the best evidence of efficacy.
  • Acceptable alternatives include daily self-administered INH for 6 months (6INH), and daily self-administered INH and rifampin (RMP) for 3-4 months.
  • Recent publications have reported good efficacy of a new regimen of 12 doses of INH and rifapentine (RPT) taken once weekly under direct observation. However, RPT is only available in Canada through the Special Access Program. If RPT is obtained through this program, clinicians should be aware that further evaluations of the regimen are needed, as adverse events are common, may be serious and are not well understood.
  • Directly observed intermittent INH is an acceptable option in settings or populations in which completion rates of daily self-administered INH have been poor. The efficacy of this regimen is unclear although better than placebo in randomized trials. Use of other regimens, given intermittently, has not been studied adequately.
  • Because of greater risk of hepato-toxicity in the post-partum period, treatment of LTBI should be deferred in pregnant women until 3 months postpartum unless they are at very high risk of disease (HIV-infected, close contacts, documented TST conversion). Treatment can be safely given to women who are breastfeeding.
  • Contacts of patients with INH resistance (but not RMP resistance) should be treated with 4 months daily RMP (4RMP). Contacts of patients with RMP resistance (but not INH resistance) should be treated with 9INH. Contacts of patients with both INH and RMP resistance (but not fluoroquinolone resistance) can be offered therapy with levofloxacin or moxifloxacin daily for 9 months.

General Considerations


After infection with Mycobacterium tuberculosis the risk of active tuberculosis (TB) development is influenced by the time since infection occurred, and the age and other medical conditions or therapies that affect the immune system of the person infected. Risk is highest in the first 1-2 years after infection. Risk is also high in very young children and declines rapidly in the first 5 years of life (refer to Chapter 9, Pediatric Tuberculosis). In children, adolescents and adults a number of medical conditions that result in diminished immunity will increase risk of reactivation of latent infection.

The concept that mono-therapy with INH could successfully treat LTBI and prevent TB disease was first reported by FerebeeFootnote 1. This was subsequently confirmed in more than 15 randomized trials involving more than 100,000 patientsFootnote 1. In these trials INH was effective, and excess toxicity was not detected. Because INH is also inexpensive it has become the standard first-line treatment of LTBI globallyFootnote 2-4.

Risk Factors for Reactivation of Active Disease from LTBI

As summarized in Table 1, there are a large number of conditions that increase the risk of reactivation of active TB from LTBI. Many medical illnesses and therapies can increase the risk of reactivation, but the strongest risk factor is HIV infection. The other problems have in common a reduction or suppression of immune function and include diabetes, renal failure, malnutrition, certain cancers, alcohol overuse and cigarette smoking. Medical therapies that suppress immune function, listed in Table 1, are increasingly important indications for LTBI treatment.

Table 1. Risk factors for the development of active tuberculosis among people with a positive tuberculin skin test (presumed infected with Mycobacterium tuberculosis)

Risk factor Estimated risk for TB relative to people with no known risk factor

Reference number

High risk
Acquired immunodeficiency syndrome 110 - 170 5
Human immunodeficiency virus infection 50 - 110 6, 7
Transplantation (related to immune-suppressant therapy) 20 - 74 8 - 12
Silicosis 30 13,14
Chronic renal failure requiring hemodialysis 7 - 50 15 - 18, 46, 47
Carcinoma of head and neck 11.6 19
Recent TB infection (= 2 years) 15.0 20, 21
Abnormal chest x-ray - fibronodular disease 6 - 19 22 - 24
Moderate risk
Tumour necrosis factor alpha inhibitors 1.5 - 5.8 25, 26, 43
Diabetes mellitus (all types) 2 - 3.6 27 - 29
Treatment with glucocorticoids (≥15mg/d prednisone) 4.9 30
Young age when infected (0-4 years) 2.2 - 5 31
Slightly increased risk
Heavy alcohol consumption (≥3 drinks/day) 3 - 4 32, 33
Underweight (<90% ideal body weight; for most people, this is a body mass index ≤20) 2 - 3 34
Cigarette smoker (1 pack/day) 1.8 - 3.5 35 - 38
Abnormal chest x-ray - granuloma 2 24, 39
Low risk
Person with positive TST, no known risk factor, normal chest x-ray ("low risk reactor") 1 40
Very low risk
Person with positive two-step TST (booster),
no other known risk factor and normal chest x-ray
0.5 Extrapolated from 40 and 1


The immune suppression associated with prevention of rejection confers a risk of progression to active TB nearly as great as HIV infection, with an estimated incidence of over 500/100,000 annually in a Spanish cohort undergoing solid organ transplantation (crude risk ratio [RR] 26.6 compared with the general population)Footnote 8. Some clinicians may elect to initiate treatment under close supervision before liver transplantation in candidates with compensated cirrhosis, according to limited safety dataFootnote 41.

Anti-tumour Necrosis Factor (anti-TNF) Agents

Anti-TNF agents currently licensed in Canada include adalimumab (Humira®), certolizumab pegol (Cimzia®), etanercept (Enbrel®), golimumab (Simponi®) and infliximab (Remicade®). Etanercept is a soluble TNF receptor, which binds competitively with circulating TNF; the other agents are monoclonal anti-TNF antibodies.

These agents are used for the treatment of autoimmune, inflammatory conditions, notably rheumatic diseases such as rheumatoid arthritis and inflammatory bowel disease.

Since the initial report of 70 patients in whom active TB developed after infliximab treatmentFootnote 25 laboratory investigation has demonstrated that anti-TNF agents interfere with both innate and adaptive immune responses essential to containment of LTBI in granulomasFootnote 42. The incidence of active TB appears to be markedly elevated in patients with rheumatoid arthritis (RA) who are administered these medicationsFootnote 26. Comparing subjects who were receiving vs. those who were not receiving an anti-TNF agent, the RR of active TB after adjustment for age, sex, other comorbidities and other anti-rheumatic drug use was 1.5 (95% confidence interval [CI] 1.1-1.9) . However, a Spanish registry study comparing RA patients who received vs. those who did not receive an anti-TNF agent estimated a crude incidence rate ratio of 5.8 (95% CI 2.5-15.4)Footnote 43. It is clear that patients who begin anti-TNF treatment are at higher risk of TB disease than the general population. There are also limited observational data that suggest systematic screening and treatment of LTBI in these individuals successfully reduces the risk of active TBFootnote 43.


Systemic corticosteroids are administered for a variety of inflammatory conditions, either transiently for flares (as in asthma) or as long-term maintenance treatment (e.g. for rheumatic diseases). As with the anti-TNF agents, systemic corticosteroid use substantially increases the risk of active TB; the risk increases with the amount taken daily and with duration/cumulative dose. For example, patients receiving a daily dose of <15 mg prednisone had an adjusted odds ratio (AOR) of 2.8 (95% CI 1.0-7.9) for development of active TB compared with non-users, and for those taking a highest daily dose of ≥15 mg the AOR was 7.7 (2.9-21.4)Footnote 30. Although subjects received systemic corticosteroids for varying durations, risk was clearly elevated with even a single prescription. In another pharmacoepidemiologic study, the adjusted RR for active TB with systemic corticosteroid use (any dosage) was 2.4 (95% CI 1.1-5.4) among RA patients. Similar risks were observed in patients who were new users, defined as 90 days or less since first prescriptionFootnote 44.

Use of inhaled corticosteroids is associated with more modest risk of active TB (adjusted rate ratio 1.48, 95% CI 1.11-1.97), although this finding was dose related, with an adjusted rate ratio of 1.97 (1.18-3.30) for the highest dose, i.e. ≥1,000 micrograms fluticasone equivalent dailyFootnote 45.

As with anti-TNF agents, everyone who is started on a regimen of systemic corticosteroids at daily doses of ≥15 mg prednisone equivalent for 1 month or longer should first be tested for LTBI. However, given the more modest effect of inhaled corticosteroids, screening for LTBI among users is not recommended.

Chronic Renal Failure and Hemodialysis

Patients with end-stage renal disease receiving hemodialysis are at substantially elevated risk of active TB, with cited relative risks ranging from 7-50 times the background incidenceFootnote 46. A recent Greek study estimated an RR of over 30 after adjustment for age, body mass index and diabetesFootnote 47. This relates to impaired immunity in the context of chronic uremia.

Radiographic Scarring

Individuals with fibronodular scarring on chest radiography are at substantially increased risk of TB reactivation, in the absence of previous treatment. Estimated RRs range from 6 to 19. Footnote 22 Footnote 24


With the growing frequency of obesity and overweight in Canada, the prevalence of diabetes is increasing. It is estimated that over 2 million people in Canada carry the diagnosis of diabetes (over 6% of the Canadian population). Prevalence increases with age, particularly after age 40; the estimated prevalence now exceeds 20% in the 75-79 age groupFootnote 50. In addition, the prevalence of diabetes may be elevated in some immigrant and some Aboriginal populations, which also have a higher prevalence of TB infection (refer to Chapter 12, Contact Follow-up and Outbreak Management in Tuberculosis Control, and Table 1 in Chapter 13, Tuberculosis Surveillance and Screening in High-Risk Populations). For example, in a population-based Ontario study, immigrants from South Asia had an adjusted RR of diabetes of 3-4 compared with Canadian-born residents; among those from Latin America, the Caribbean and sub-Saharan Africa the RR was approximately 2.0Footnote 51. A meta-analysis by Jeon and Murray estimated that active TB was 3 times more likely in diabetics than non-diabetics, after adjustment for ageFootnote 52. A more recent meta-analysis by Baker and colleagues estimated relative risks ranging from 1.7 to 5 for treatment failure, relapse and death among diabeticsFootnote 53.


In a recent systematic review and meta-analysis of 18 studies of the risk of active TB development in patients with cancer, the risk compared with the general population was high (incidence rate ratio [IRR] 11.6; 95% CI 7.0-19.2)Footnote 19. The relative risk of active TB was markedly increased for all types of cancer although not significantly increased  for solid tumours: risk for hematologic malignancies (IRR = 29.6 [11.6-75.7]), solid tumours (IRR = 17 [0.7-391]) and stem cell transplants for hematologic malignancies or hematologic disorders (IRR = 5.3 [2.6-10.9]). The risk of TB in patients with head and neck cancer is difficult to quantify as the studies describing this relationship were not comparable with each other or with other studies included in the review, and the reported cumulative incidence took place over variable periods of time rather than being an annual risk of diseaseFootnote 54-56.

On the basis of these findings, patients with all types of hematologic malignancies and bone marrow transplant for hematologic malignancy should be offered screening for LTBI, but there is insufficient evidence to offer LTBI screening and treatment to patients with solid tumours.

Tobacco and Alcohol

Tobacco smoking is associated with increased risk of LTBI (estimated RR 1.7-1.9), active TB disease (RR 2.0-2.7) and death from TB (RR 2.6), according to two recent meta-analysesFootnote 35-Footnote 37. Another recent meta-analysis suggested that heavy alcohol use (>40 g/day) is also associated with an increased risk of active TB (RR 2.9, 95% CI 1.9-4.6)Footnote 57.

Indications for Treatment of LTBI

For consideration of LTBI treatment in an individual patient the risk factors reviewed above and listed in Table 1 are important, as the degree of risk will determine the potential benefit from LTBI treatment. There are two categories of indications for LTBI treatment: recent infection and increased risk of reactivation. Reactivation risks have been considered above; recent infection is common in contacts of patient with active contagious TB (also, refer to Chapter 12). This is also seen in people with documented TST conversion from negative to positive (refer to Table 2; also, refer to Chapter 4, Diagnosis of Latent Tuberculosis Infection), such as health care workers.

Table 2. Tuberculin skin test cut-points for treatment of latent TB infection
TST result IndicationA
Table 2 - Footnote A
Age ≥35 years is not a contraindication to treatment of LTBI if the risk of progression to active TB disease is greater than the risk of serious adverse reactions to treatment.
Table 2 - Footnote B
Treatment with INH of people with HIV infection who were TST negative (0-4 mm) and/or anergic was of no benefit in several randomized trials. Other authorities suggest this treatment may be considered in the presence of HIV infection or other cause of severe immunosuppression AND high risk of TB infection (contact with infectious TB, from high TB incidence country or abnormal chest x-ray consistent with prior TB infection). Hence any decision to give treatment should be individualized in consultation with a TB expert.
Table 2 - Footnote C
If first TST is negative, begin treatment immediately. Repeat TST 8 weeks after exposure to infectious TB case ended. Treatment can be stopped in a healthy child if repeat TST is negative. (<5 mm induration). In children <6 months of age the immune system may not be mature enough to produce a positive TST, even if the child is infected (refer to Chapter 9, Pediatric Tuberculosis).
Table 2 - Footnote G
LTBI therapy is often given to people in whom transplantation is planned but before the actual transplantation.
0-4 mm In general this is considered negative and no treatment is indicatedB
Close contacts in children less than 5 years of age should be treated pending results of repeat skin test 8 weeks after exposureC
≥5 mm HIV infection
Contact with infectious TB within the past 2 years
Fibronodular disease on chest x-ray  (healed TB and not previously treated)
Organ transplantation (related to immune suppressant therapy)G
TNF alpha inhibitors
Other immunosuppressive drugs, e.g. corticosteroids (equivalent of ≥15 mg/day of prednisone for 1 month or more; risk of TB disease increases with higher dose and longer duration)
End-stage renal disease
≥10 mm TST conversion (within 2 years)
Diabetes, malnutrition (<90% ideal body weight), cigarette smoking, daily alcohol consumption (>3 drinks/day)
Hematologic malignancies (leukemia, lymphoma) and certain carcinomas (e.g. head and neck)

However, if considered from a public health perspective, treatment of some of these high-risk conditions will have little impact at a population level. This is because the total number of cases attributable to each of these conditions is determined by not only the risk but also the prevalence of the condition. As summarized in Table 3, the World Health Organization has estimated that some widely prevalent conditions contribute more cases than HIV infection to the global burden of TBFootnote 58. Hence, if LTBI treatment of everyone who is malnourished, has diabetes or smokes cigarettes were possible, then this would have the greatest public health impact.

Table 3. Impact of risk factors on the global burden of tuberculosis
(adapted from Lonnroth et al Footnote 58.)
Risk factor Relative risk
(compared with healthy person)
Population attributable  fraction
HIV infection 35-110 11%
Malnutrition 2-3 27%
Diabetes 3-4 8%
Alcohol abuse 2-3 10%
Cigarette smoking 2-2.5 16%

LTBI Treatment if Immune Compromised and TST is Negative

Multiple randomized trials have compared INH with placebo in HIV-infected individuals who are TST positive or TST negative. Five of these trials were summarized in a meta-analysis. The pooled estimate of reduction in disease compared with placebo was 14% in HIV-infected individuals who were initially TST negative and more than 60% in those who were initially TST positive; the latter finding was significantFootnote 59. These findings were recently confirmed in a large-scale trial in Botswana, in which benefit of INH for 36 months was demonstrated only in those with initial TST of 5 mm or greater (positive)Footnote 60. Two trials have compared rate of disease following INH or placebo in HIV-infected individuals who had no response to tuberculin antigens (i.e. were TST negative) or to a panel of common antigens (i.e. were anergic)Footnote 61 Footnote 62. In both trials there was no significant benefit of INH treatment.

Hence, based on these studies, LTBI therapy is not indicated for individuals who are immune compromised and TST negative. In certain circumstances a severely immune compromised patient may be considered at such a high risk of infection and subsequent disease that LTBI treatment may be given presumptively, even with a negative TST or in the absence of a TST. Such treatment should be carefully considered by balancing the risks and benefits on an individual basis.

Adverse Events of the Drugs Used to Treat LTBI

(Refer to Chapter 5, Treatment of Tuberculosis Disease).

Recommendations for Treatment

Recommendations for LTBI treatment are summarized in Table 4. The evidence, from randomized trials, in support of these recommendations is summarized in Table 5.

Standard Regimen

The standard regimen of first choice is 9 months of daily self-administered INH (9INH).
(Strong recommendation, based on strong evidence)

INH is still considered the standard first-line therapy, given its long history of use, well- known safety profile and demonstrated efficacy in multiple randomized trials conducted in HIV-infectedFootnote 59 Footnote 80 and HIV-uninfected populationsFootnote 1 Footnote 81 in many settings.

INH is usually self-administered daily. The optimal duration based on a reanalysis by Dr. George Comstock of data from trials among Alaskan Inuit appears to be 9 monthsFootnote 71. In this reanalysis, protective efficacy against reactivation of TB progressively increased with longer duration of INH, up to a maximum of 90% with 9 months' therapy; there was no further improvement in efficacy with longer duration of therapyFootnote 71.

Pyridoxine (vitamin B6) should be given to minimize the risk of neuropathy in people with risk factors for pyridoxine deficiency (such as malnourished or pregnant individuals) or for neuropathy (patients with diabetes or renal insufficiency). B6 supplements are not routinely needed otherwiseFootnote 3.

INH treatment is associated with two major problems. The first is toxicity, particularly hepatotoxicity, which can be fatal. The second problem is the long duration. These two problems result in poor acceptance of this therapy by patients and providers, and poor completion rates by patients. As a result there has been substantial interest and research in shorter regimens that are safer than and at least as effective as INH.

Shorter Alternative Regimens

Six months of daily, self-administered INH (6INH) is an acceptable alternative.
(Strong recommendation, based on strong evidence)

This regimen has been documented to achieve better completion rates but has a protective efficacy of only 67%Footnote 73 or 69%Footnote 63. In Canada 6INH should be considered a regimen of second choice, even if this regimen is recommended by authorities elsewhereFootnote 4.

Three or 4 months of daily, self-administered INH and RMP (3-4INH/RMP) is also an acceptable alternative.
(Strong recommendation, based on strong evidence)

A number of randomized trials have compared the efficacy and safety of daily self-administered INH and RMP taken together for 3-4 months. These results have been summarized in a recent systematic review meta-analysis, which found that the efficacy and safety of this regimen was similar to 6 to 9 months of INHFootnote 82.

Three months of once weekly, directly observed INH and RPT (3INH/RPT) has acceptable efficacy, but because of high rates of poorly understood hypersensitivity reactions should be used only with very close monitoring.
(Conditional recommendation, based on moderate evidence)

RPT is a rifamycin with a half-life that is 5 times longer than that of RMP. Hence, it can be given as infrequently as once weeklyFootnote 69. The 3INH/RPT regimen has been assessed in three randomized trials. In these trials every dose was directly observed, whereas the comparator regimen of INH was self-administered daily. The first, conducted in Brazil, found that this regimen was slightly but not significantly worse than 6 months of INH in preventing active disease among close contacts, with similar toxicityFootnote 79. The second, published in 2011, was conducted in South Africa and reported similar efficacy and toxicity but better completion than 6INHFootnote 74. The third and largest trial involved more than 8,000 mostly HIV-uninfected individuals in the United States, Canada and Spain. In this trial the 3INH/RPT regimen was as efficacious as 9INH, with significantly better completion rates and significantly less hepatotoxicityFootnote 69. Interestingly, the overall rate of serious adverse events was actually higher with the 3INH/RPT regimen because of an excess occurrence of hypersensitivity reactionsFootnote 69.

In summary, the evidence to date indicates that this is a very promising regimen that is well accepted, has high completion rates and shows efficacy that is similar to that of 9 months of INH. However, every dose should be directly observed, which can be difficult to organize in some practice settings or populations. More importantly, the occurrence of hypersensitivity reactions, which can be severe, is unexplained. Until this problem is better understood the regimen should be used ONLY under carefully monitored circumstances; patients who are prescribed this regimen should be questioned carefully, before administration of each dose, about any problems that were related to the preceding dose. Therefore, the regimen is not recommended at this time for general use. It is hoped that these adverse reactions will be better understood with more use of the regimen, allowing them to be prevented and/or managed more easily. A second barrier is that RPT is only available in Canada through Health Canada, Special Access Program, Drugs and Health ProductsExternal site.

Four months of daily, self-administered RMP (4RMP) can be used as an alternative, given excellent safety but uncertain efficacy.
(Conditional recommendation, based on moderate evidence)

In the United States and Canada 4RMP has been recommended as an alternative regimen since 2000Footnote 2 Footnote 3. Experience with the regimen under program conditions has been good; completion rates have been substantially and significantly better than for 9INH with very low toxicity, particularly hepatotoxicityFootnote 83 Footnote 84. Two randomized trials have demonstrated superior completion and lower adverse event ratesFootnote 68 Footnote 77. To date, a single randomized trial has evaluated the efficacy of this regimenFootnote 13: 3 months of RMP were compared with 6 months of INH, 3 months of INH/RMP, and placebo. A 63% reduction in disease was achieved with 3RMP, better than the other two regimens and significantly better than placeboFootnote 13. There are no published data on the efficacy of 4RMP, although a large-scale international trial comparing the efficacy of 4RMP and 9INH is ongoing; the results will only be available in 2016. It is anticipated that the efficacy of 4RMP should be better than that of 3RMP, making it close to that of 9INH. Given the consequences of RMP resistance, careful exclusion of active TB is even more important if this regimen is used.

Two months of daily, self-administered rifampin/pyrazinamide (2RMP/PZA) should NOT be used.
(Strong recommendation, based on strong evidence)

In 1989 this regimen was reported to be highly effective in a mouse model of LTBFootnote 85. Several randomized trials were subsequently conducted comparing this regimen  with placebo or INH (with varying duration) in HIV-infected populationsFootnote 71 Footnote 73 Footnote 75. The 2RMP/PZA regimen had efficacy and toxicity similar to those of the comparator INH regimens. Following recommendations for the use of 2RMP/PZAFootnote 3 the regimen was adopted enthusiastically by providers and patients. Within a year numerous reports were published of severe, even fatal, hepatotoxicity with use of 2RMP/PZAFootnote 86 Footnote 87. This led to revised recommendations to restrict its useFootnote 88 Footnote 89. The regimen is not recommended in Canada.

Intermittent Regimens

To enhance the feasibility of directly observed therapy, intermittent LTBI regimens have been assessed in a few randomized trials. Given twice weekly, 6INH resulted in significant reduction of disease compared with placebo in two trials in HIV-infected individualsFootnote 75 Footnote 76. In the only published trial that has directly compared intermittent with daily INH, thrice weekly 6INH was somewhat less effective than daily 6INH in HIV-infected childrenFootnote 91. This difference was not significant, but statistical power was limited because the trial was stopped early as a result of a very high rate of disease in the placebo arm. Twice weekly directly observed INH and RMP for 6 months was significantly superior to daily self-administered INH for 12 months in a non-randomized observational study in SaskatchewanFootnote 91.

On the basis of this limited evidence it appears that intermittent regimens with INH offer some benefit relative to nothing (placebo control), but their efficacy relative to daily INH has not been adequately assessed.

Hence, intermittent, directly observed regimens with INH or INH/RMP should be considered alternative regimens and used in selected circumstances or populations where daily, self-administered regimens have had limited success.
(Conditional recommendation, based on weak evidence)

As with active TB, all doses of intermittent regimens for LTBI should be directly observed.

Table 4. Summary of recommended regimens for LTBI treatment
Drug(s)Footnote A Duration Schedule Mode of administration Level of evidenceFootnote B
INH = isoniazid, RMP = rifampin, RPT = rifapentine, SAP = self-administered prophylaxis, DOP = directly observed prophylaxis.
Table 4 - Footnote A
For doses of these drugs refer to Chapter 5.
Table 2 - Footnote B
Evidence for each regimen is summarized in Table 5. Level 1: multiple randomized trials; Level 2: single randomized trial and/or multiple observational (cohort) studies.
Table 2 - Footnote C
Use this regimen with careful monitoring for hypersensitivity reactions - these can be severe. RPT is only available in Canada through the Special Access Program.
Standard regimen
INH 9 months Daily SAP 1
Acceptable alternative regimens
INH 6 months Daily SAP 1
INH/RMP 3 months Daily SAP 1
INH/RPTFootnote C 3 months Once weekly DOP 1
RMP 4 months Daily SAP 2
INH 6-9 months Twice weekly DOP 2
INH/RMP 3 months Twice weekly DOP 2

Table 5. Summary of evidence to support recommendations
(data taken only from published randomized trials)
Regimen Duration Completion Adverse events EfficacyFootnote A
INH = isoniazid, RMP = rifampin, PZA = pyrazinamide, RPT = rifapentine, Eq = equivalent to,
12INH = 12 months INH, 9INH = 9 months INH, 6INH = 6 months INH, 2RMP/PZA = 2 months RMP & PZA
Table 2 - Footnote A
Efficacy estimated from placebo controlled trials or listed as (EqNx), meaning equivalent to the comparator regimen. Estimates shown are for TST-positive patients if these results are provided.
Table 2 - Footnote B
Study in children
Table 2 - Footnote C
Halsey et al.:Footnote 75 half of the doses were supervised. Mwinga et al:Footnote 76 fully supervised treatment (DOPT).
Table 2 - Footnote G
RPT available in Canada only through Special Access Program, refer to text.
12 months 68%Footnote 63
69%Footnote 64
85%Footnote 65
5.2%Footnote 63
6.1%Footnote 64
67%Footnote 66
93%Footnote 63
9 months 57%Footnote 67
60%Footnote 68
62%Footnote 63
69%Footnote 69
86%Footnote 70
0Footnote B Footnote 70
3.7%Footnote 69
4.0%Footnote 68
90%Footnote 71
6 months 63%Footnote 61
65%Footnote 72
73%Footnote 13
75%Footnote 73
78%Footnote 63
84%Footnote 74
0.6%Footnote 73
1.9%Footnote 74
2.8%Footnote 61
3.6%Footnote 63
7%Footnote 72
8%Footnote 13
67%Footnote 63
68%Footnote 73
(twice weekly)
6 months 55%Footnote C Footnote 75
72%Footnote C Footnote 76
0Footnote 75
3%Footnote 76
Eq2RMP/PZAFootnote 75
40%Footnote 76
4 months 76%Footnote 13
80%Footnote 68
86%Footnote 77
0Footnote 13
1.5%Footnote 68
63%Footnote 13
(daily or twice weekly)
3 months 63%Footnote 67
69%Footnote 72
75%Footnote 73
76%Footnote 13
95%Footnote C Footnote 74
97%Footnote 78
0Footnote C Footnote 70
2.3%Footnote 73
3.8%Footnote 74
5%Footnote 13
7%Footnote 78
10%Footnote 67
18%Footnote 72
64%Footnote 73
Eq6INHFootnote 13 Footnote 72 Footnote 74
Eq9INHFootnote 67
Eq12INHFootnote 78
INH/RPTFootnote A
(Once weekly)
3 months 82%Footnote C Footnote 69
95%Footnote C Footnote 79
96%Footnote C Footnote 74
1.0%Footnote 79
1.8%Footnote 74
4.9%Footnote 69
Eq 2RMP/PZAFootnote 79
Eq 6INHFootnote 74
Eq 9INHFootnote 69

Older Age and LTBI Treatment

There is a well-recognized relationship between older age and greater risk of adverse events, particularly hepatotoxicity, during treatment with INH. This relationship was noted in the 1970sFootnote 92 Footnote 93 and in more recent studiesFootnote 94 Footnote 95. In one of the earliest surveillance studies mortality from INH hepatitis was reported only in individuals over the age of 35Footnote 93. This well-known but post-hoc analysis has resulted in the common misconception that only patients under 35 should be treated. However, there is no age at which there is zero risk - hepatotoxicity has been reported in young childrenFootnote 96, although this is rare (<1 per 1,000). In a recent study patients over the age of 50 had increased rates of hospitalization attributable to liver toxicity from INHFootnote 95. In patients 65 and older, 2.6% were hospitalized for INH-associated hepatotoxicity. The greatest risk of hepatotoxicity was in the elderly with comorbidities; those without comorbidities under the age 65 had low rates of hepatotoxicity that were not age dependentFootnote 95.

As shown in Table 6, the number of patients needing to be treated before harm, rather than good, is caused is more than 100 in those aged under 35, but falls within the range of 9-15 in the elderly.

Patients who are under 65 years old and have no comorbidities should be offered LTBI treatment if they are at moderate or higher risk.
(Conditional recommendation, based on moderate evidence)

However, the risks and benefits should be considered very carefully in people over the age of 65, although therapy may be reasonable in those at high risk of reactivation and without comorbidities. At any age the risk of toxicity should be weighed against the benefit of therapy. In older people with greater risk of toxicity, therapy is indicated only if the risk of disease is high, meaning that they must have recent infection or medical risk factors for reactivation. As an example, a 25-year-old healthy individual with no risk factors for reactivation (detected through pre-employment screening) may be considered for LTBI treatment, but the risks might exceed the benefits if, instead, they were 45 years old. However, the benefits of INH therapy will exceed the risks of toxicity at almost any age in an HIV-infected individual. The reader is referred to a useful on-line tool that may assist in the assessment of likely risk of disease and adverse events in an individual (refer to the online TST/IGRA interpreterExternal site).

Table 6. Estimated number needed to harm with isoniazid treatment for LTB, with increasing risk of INH hepatotoxicity
(derived from published toxicity estimates)
Age range Incidence of
hepatotoxicity (%)
NumberFootnote A 95% Confidence interval
<20 yrs 0.10 268 69-2513
0.20 134 35-1256
20-34 yrs 0.25 107 28-1005
35-49 yrs 0.5 54 14-503
0.75 36 9-335
50-64 yrs 1.0 27 7-251
1.25 21 6-201
1.50 18 5-168
1.75 15 4-144
≥65 yrs 2.0 13 3-126
2.25 12 3-112
2.5 11 3-101
2.75 10 3-91
3.0 9 2-84
Risk of hepatotoxicity increases with age:
<20 yrs: 0.1%-0.2%Footnote 97-103
20-34 yrs: 0.3%Footnote 104-106
35-49 yrs: 0.5%Footnote 104-106
50-64 yrs: 1%-3%Footnote 104-106
≥65 yrs: 2%-5%Footnote 95 Footnote 107 Footnote 108
Table 6 - Footnote A
Number of patients needing to be treated before harm, rather than good, is caused.

Pregnancy or Breastfeeding and LTBI Treatment

INH and RMP are considered safe in pregnancy, although the mother should be given pyridoxine (vitamin B6) supplements.
(Strong recommendation, based on moderate evidence)

An increased risk of hepatotoxicity from INH has been reported in women treated during the first 3 months postpartumFootnote 109.

Hence, deferral of treatment of LTBI until 3 months after delivery is recommended unless there is very high risk of development of disease, such as HIV infection or recent infection (conditional recommendation, based on weak evidence).

Breastfeeding is considered safe for mothers taking INH or RMP, and they should also take pyridoxine (vitamin B6) supplements. Approximately 3% of the maternal dose is excreted in breast milkFootnote 110. This means that even a newborn will not be exposed to a significant dose of INH.

Duration of Therapy (in HIV-infected Individuals)

In settings with a very high incidence of TB disease and accordingly high rates of transmission of TB infection, the benefits of INH therapy for LTBI have not extended far beyond the end of therapy in HIV-infected people. Several trials have examined a longer duration of INH. In Botswana, TST-positive, HIV-infected individuals were randomly assigned to 36 months of INH (36INH) or 6INH followed by 30 months of placeboFootnote 60. The 36INH regimen was associated with substantially and significantly lower rates of disease, but only in subjects who were initially TST positiveFootnote 60. In a second study in South Africa, lifelong INH in TST-positive, HIV-infected people was more efficacious than 6INHFootnote 74. However, adverse events were much more common, and compliance fell progressively over time Footnote 74. In Canada such high transmission rates are rarely, if ever, encountered (refer to the Public Health Agency of Canada, Tuberculosis in Canada 2010, Pre-ReleaseExternal site web site).

Prolonged therapy with INH, beyond the standard 9 months, is not recommended in Canada.
(Strong recommendation, based on moderate evidence)

Treatment of Presumed Drug-resistant LTBI

(Also, refer to Chapter 8, Drug-Resistant Tuberculosis.)

The question of how to treat presumed drug-resistant (DR) LTBI usually arises in patients who are close contacts of index cases with known drug-resistant TB. There have been no randomized trials of treatment of contacts of any form of DR-TB. Hence, all the recommendations in Table 7 are based on expert opinion rather than evidence of efficacy.

Table 7. Recommended regimens for contacts of drug-resistant index cases
Drug resistance pattern of index case Recommended regimenFootnote A Level of evidenceFootnote B
PZA = pyrazinamide, EMB = ethambutol, INH = isoniazid, RMP = rifampin, 9INH = 9 months daily INH, 4RMP = 4 months daily rifampin, 6FQN = 6 months daily fluoroquinolone
Table 2 - Footnote A
All regimens are suggested to be self-administered and taken daily.
Table 2 - Footnote B
Level of evidence: 1 = multiple randomized trials, 2 = single trial and multiple observational studies, 4 = expert opinion only.
PZA and/or EMB 9INH 1
Mono INH 4RMP 2
Polydrug resistance including INH 4RMP 1
Mono RMP resistance (INH susceptible) 9INH 1
MDR (INH and RMP resistant) 9 FQN: levofloxacin or moxifloxacin 4

Simply stated, contacts of patients with INH resistance (but not RMP resistance) should be treated with 4RMP.
(Conditional recommendation, based on weak evidence)

Contacts of patients with RMP resistance (but not INH) should be treated with 9INH.
(Strong recommendation, based on strong evidence)

For contacts of patients with multidrug-resistant (MDR) TB, a combination of a later generation fluoroquinolone (FQN) and pyrazinamide (PZA) has been recommendedFootnote 3. However, two case series reported very high rates of toxicity and intolerance, and very poor completion rates with this regimen, possibly as a result of the effects of PZAFootnote 111 Footnote 112.

Daily use of levofloxacin or moxifloxacin for 9 months (conditional recommendation, based on very weak evidence) is recommended, based on evidence that later generation FQN are generally well tolerated and can adequately replace INH in active TB therapyFootnote 113. However, the tolerability and safety of long-term use of FQN are not well known; patients should be advised of this and monitored closely for adverse events.

Contacts presumably infected with an MDR-TB isolate should be thoroughly educated about symptoms and signs of TB, and the need for immediate medical evaluation if symptoms occur. Because of the limited amount of information about the efficacy of preventive therapy in individuals likely to be infected with an MDR-TB strain, contacts should be followed closely for the 2 years immediately after infection. Contacts of MDR-TB patients who do not accept or tolerate TB preventive therapy or in whom there is no preventive therapy (the source case isolate is resistant to all first- and second-line drugs) should be carefully followed over a period of 2 years (e.g. at 6, 12 and 24 months) for the appearance of signs and symptoms of active disease.

Therapy if There is Renal or Liver Disease

Therapy for LTBI with INH or RMP does not need to be adjusted for renal insufficiencyFootnote 2 Footnote 3.

Mild hepatic dysfunction is a relative contraindication for INH therapy. In such patients, RMP may be a better choice than INH in view of its lower hepatotoxicity in randomized trialsFootnote 13 Footnote 68 and observational studiesFootnote 83 Footnote 84. In patients with severe hepatic dysfunction, INH, RMP and RPT should be avoided altogether. Instead, daily levofloxacin or moxifloxacin for 9 months may be used on the basis of evidence that these agents can replace INH in therapy of active TB;Footnote 113 their efficacy for LTBI is unknown. Generally, these agents are very well tolerated, although in a recent report their use was associated with an incidence of hepatotoxicity of approximately 4 per 100,000Footnote 114.

Follow-up and Monitoring During LTBI Therapy

For patients receiving self-administered treatment of LTBI the prescription for medication should not exceed a 1-month supply of doses. Exceptions can be made, such as if a patient is travellingFootnote 2 Footnote 3.

There are two main objectives of follow-up during LTBI therapy: (i) early detection and management of adverse events; and (ii) monitoring and enhancing compliance. Practice varies widely, but contact with patients is recommended every month, at least by telephone if not in personFootnote 2 Footnote 3. Monitoring of liver function tests is controversial, but the consensus of expert opinion is reflected in Table 8 (all the recommendations in Table 8 are conditional, based on expert opinion, i.e. very weak evidence). If liver transaminases increase beyond 5 times the upper limit of normal (or 3 times in the presence of symptoms) the LTBI regimen should be stopped. (Detailed suggestions for management of adverse events are found in Chapter 5: Treatment of Tuberculosis Disease.)

Adherence can be monitored in several ways. Patients' self-report is notoriously unreliable, as is health care provider assessmentFootnote 115. Pill counts are somewhat more reliable, although patients can discard pills rather than swallow them. Urine tests can be performed to detect INH or RMP metabolites. Devices that monitor each time that doses are withdrawn from pill bottles are the most reliable,Footnote 116 Footnote 117 but expensive; simple, reliable devices are still under development. At present there is no perfect way to monitor adherence.

It has been observed that there are large differences in rates of completion of LTBI therapy between programs. Programs with higher rates of completion emphasize patient-centred care, with close follow-up, frequent reminders of the importance of therapy and constant encouragement to complete therapyFootnote 3.

Although rare, severe hepatotoxicity requiring transplantation or leading to death has occurred during INH treatment of LTBIFootnote 118. Therefore, it is recommended that patients receiving INH therapy should be provided with a clear written plan of action, including contact telephone numbers, should symptoms arise. This plan, which should be reinforced by the prescribing health care provider, should recommend that patients contact their health care provider immediately if they have symptoms such as anorexia, nausea, vomiting, abdominal discomfort, unexplained fatigue, dark-coloured urine, scleral icterus or jaundice. If they cannot reach their provider they should stop the INH until they have been seen and evaluated. Evaluation should include a physical examination and investigation of liver transaminase values and bilirubin levels.

Table 8. Suggested follow-up schedule for patients receiving 9INH latent TB treatmentFootnote A
(Conditional recommendations, based on very weak evidence)
Actions Start of treatment 1 month 2 month 3 month 4 month 5 month 6 month 7 month 8 month 9 month
Table 2 - Footnote A
Schedule is for treatment with 9INH. If alternative regimen is used, suggest same schedule until end of therapy. All recommendations in this table are based solely on expert opinion.
Table 2 - Footnote B
These include pregnancy or first 3 months postpartum, history of previous drug-induced hepatitis, current cirrhosis or chronic active hepatitis of any cause, hepatitis C, hepatitis B with abnormal transaminases, daily alcohol consumption or concomitant treatment with other hepatotoxic drugs (e.g. methotrexate). HIV infection is not an independent risk for drug-induced hepatitis.
Medical evaluation X X X If
X If
X If
X If
Telephone call to patient       X   X   X   X
Compliance assessment   X X If
X If
X If
X If
Chest radiography X                  
Bilirubin, transaminases
Age <35 If
clinical suspicion of liver disease
Age 35-50 X X If
  If needed X
Age >50 or other risk factorsFootnote B X X X X X X X X X X

Documentation of Treatment of LTBI

The drug, dosage, interval (daily, 2x/wk, 3x/wk), mode (directly observed or self-administered), start date, end date and total number of doses taken should be recorded.

Follow-up after LTBI Treatment and Management Following Re-exposure

There is no need for routine follow-up after completion of LTBI treatment. If a patient refuses or does not complete therapy, then he or she should be instructed carefully regarding the principal symptoms of active TB and instructed to return for evaluation if those symptoms arise. Routine chest radiography has very low yield and is not recommended (refer to Chapter 3: Diagnosis of Active Tuberculosis and Drug Resistance).

If patients are re-exposed through contact with a case of active contagious TB, there is no value in repeating the tests for LTBI infection ("once positive = no longer useful"Footnote 119).

In immunocompetent people there is evidence that a first episode of TB infection provides approximately 80% protection against development of disease following re-exposureFootnote 120. This benefit is similar to that achieved with 9 months of INH therapyFootnote 71.

Hence, a second course of LTBI treatment is not recommended, even if the re-exposure was close/intense and even if exposure was to a drug-resistant case.
(Conditional recommendation, based on very weak evidence)

However, if there is uncertainty that a previous course of LTBI therapy was taken adequately, then it may be prudent to recommend the patient take a full course of LTBI therapy.
(Conditional recommendation, based on very weak evidence)

In immune compromised individuals, such as HIV-infected people or very young children (under 5), there may not be any effective immunity conferred by prior TB infection.

Therefore, it is recommended that these individuals could be considered for a second course of LTBI treatment.
(Conditional recommendation, based on very weak evidence)

However, this recommendation is not based on any published evidence that such treatment is effective, nor is there broad consensus on the benefits of retreatment of LTBI following re-exposure. Further considerations include how well the individual tolerated previous LTBI treatment, likely adherence to another course of treatment and probable public health consequences if active TB develops.

Does Treatment of LTBI Create Drug Resistance?

This is a commonly asked question, particularly when dealing with a population with historically low rates of LTBI treatment completion. A systematic review of 13 randomized trials found that the rate of disease with INH-resistant strains was somewhat but not significantly higher in those assigned to INH than to placeboFootnote 121. In a subsequently published trial among HIV-infected people, those assigned to 36 months of INH had a similar rate of INH-resistant TB as the group assigned to 6 months of INHFootnote 60. As well, a large cohort study in the United States found no evidence of increased INH resistance, simply that INH was ineffective in preventing INH-resistant TBFootnote 122. In all studies disease was most likely to develop in those who did not complete INH; hence, the evidence is consistent that INH therapy of LTBI, even when inadequately taken, does not lead to the emergence of resistance. Of course, in all these studies active disease was carefully excluded before mono-INH was begun.

Program Indicators

The ideal LTBI treatment delivery program will achieve, at a minimum, 80% acceptance of treatment among people with LTBI in whom treatment is indicated, and at least 80% of those starting will complete the required number of dosesFootnote 2 Footnote 3.


Footnote 1
Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. Adv Tuberc Res 1969;17:28-106.
Footnote 2
Long RL, Ellis E, eds. Canadian Tuberculosis Standards (6th edition). Ottawa: Canadian Lung Association, Public Health Agency of Canada, Tuberculosis Prevention and Control, 2007.
Footnote 3
American Thoracic Society. Targeted tuberculin testing and Treatment of Latent Tuberculosis Infection. Am J Respir Crit Care Med 2000;161:S221-S247.
Footnote 4
World Health Organization. Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva: World Health Organization, 2011
Footnote 5
Guelar A, Gatell JM, Verdejo J, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993;7:1345-49.
Footnote 6
Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1 - infected adults from communities with low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000;23:75-80.
Footnote 7
Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320(9):545-50.
Footnote 8
Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid organ transplant: incidence risk factors, and clinical characteristics in RESITRA (Spanish network of infection in transplantation) cohort. Clin Infect Dis 2009;48(12):1657-65.
Footnote 9
Sakhuja V, Jha V, Varma PP, Joshi K, Chugh KS. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation 1996;61(2):211-15.
Footnote 10
Aguado JM, Herrero JA, Gavalda J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997;63(9):1278-86.
Footnote 11
Miller RA, Lanza LA, Kline JN, Geist LJ. Mycobacterium tuberculosis in lung transplant recipients. Am J Respir Crit Care Med 1995;152(1):374-76.
Footnote 12
Meyers BR, Halpern M, Sheiner P, Mendelson MH, Neibart E, Miller C. Tuberculosis in liver transplant patients. Transplantation 1994;58(3):301-306.
Footnote 13
Hong Kong Chest Service Tuberculosis Research Centre MBMRC. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41.
Footnote 14
Cowie RL. The epidemiology of tuberculosis in gold miners with silicosis. Am J Respir Crit Care Med 1994;150:1460-62.
Footnote 15
Maholtra KK, Parashar MK, Sharma RK, et al. Tuberculosis in maintenance haemodialysis patients. Study from an endemic area. Postgrad Med J 1981;57(670):492-98.
Footnote 16
Lundin AP, Adler AJ, Berlyne GM, Friedman EA. Tuberculosis in patients undergoing maintenance hemodialysis. Am J Med 1979;67(4):597-602
Footnote 17
Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH. Tuberculosis in patients with end-stage renal disease. Am J Med 1980;68(1):59-65.
Footnote 18
Pradhan RP, Katz LA, Nidus BD, Matalon R, Eisinger RP. Tuberculosis in dialyzed patients. JAMA 1974;229(7):798-800.
Footnote 19
Greenway C, Palayew M, Yansouni C, et al. Risk of active tunerculosis in patients with cancer: a systematic review and meta-analysis. 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), 2011.
Footnote 20
Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 1976;19:1-63.
Footnote 21
Sutherland I. The evolution of clinical tuberculosis in adolescents. Tubercle 1966;47:308.
Footnote 22
Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian refugees: a five-year surveillance study. Am Rev Resp Dis 1988;137:805-809.
Footnote 23
Grzybowksi S, McKinnon NE, Tuters L, Pinkus G, Philipps R. Reactivations in inactive pulmonary tuberculosis.  Am Rev Resp Dis 1966;93:352-60.
Footnote 24
Grzybowski S, Fishaut H, Rowe J, Brown A. Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service. Am Rev Resp Dis 1971;104:605-608.
Footnote 25
Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345(15):1098-1104.
Footnote 26
Brassard P, kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006;43(6):717-22.
Footnote 27
Kim SJ, Hong YP, Lew WJ, Yang SC, Lee EG. Incidence of pulmonary tuberculosis among diabetics. Tuber Lung Dis 1995;76(6):529-33.
Footnote 28
Silwer H, Oscarsson PN. Incidence and coincidence of diabetes mellitus and pulmonary tuberculosis in a Swedish county. Acta Med Scand 1958;161(Suppl 335):1-48.
Footnote 29
Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997;87(4):574-79.
Footnote 30
Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55(1):19-26.
Footnote 31
Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974;99(2):131-37.
Footnote 32
Lonnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use as a risk factor for tuberculosis - a systematic review. BMC Public Health 2008;8:289.
Footnote 33
Menzies D, Gardiner G, Farhat M, Greenway C, Pai M. Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int J Tuberc Lung Dis 2008;12(5):498-505.
Footnote 34
Comstock GW. Frost revisited: The modern epidemiology of tuberculosis. Am J Epidemiol 1975;101:263-382.
Footnote 35
Maurya V, Vijayan VK, Shah A. Smoking and tuberculosis: an association overlooked. Int J Tuberc Lung Dis 2002;6(11):942-51.
Footnote 36
Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from exposure to tobacco smoke. Arch Intern Med 2007;167:335-42.
Footnote 37
Lin H, Ezzati M, Murray M. Tobacco Smoke, Indoor Air Pollution and Tuberculosis: A Systematic Review and Meta-Analysis. PLOS Medicine 2007;4(1):e20.
Footnote 38
Maurya V, Vijayan VK, Shah A. Smoking and tuberculosis: an association overlooked. Int J Tuberc Lung Dis 2002;6(11):942-51.
Footnote 39
Horwitz O, Wilbek E, Erickson PA. Epidemiological basis of tubeculosis eradication. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area. Bull Wld Hlth Org 1969;41:95-113.
Footnote 40
Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the US Navy:  its distribution and decline. Am Rev Respir Dis 1974;110:572-80. Comstock+GW,+Edwards+LB,+Livesay+VT.+Tuberculosis+morbidity+in+the+US+Navy%3A++its+distribution+
Footnote 41
Singh N, Wagener MM, Gayowski T. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Transplantation 2002;74(6):892-95.
Footnote 42
Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exper Immunol 2010;161(1):1-9.
Footnote 43
Gomez-Reino JJ, Carmona L, Descalzo MA. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57(5):756-61.
Footnote 44
Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009;61(3):300-304.
Footnote 45
Brassard P, Duissa S, kezouh A, Ernst P. Inhaled corticosteriods and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2011;183:675-78.
Footnote 46
Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial 2003;16(1):38-44.
Footnote 47
Christopoulos AI, Diamntopoulos AA, Dimopouloa PA, Goumenos DS, Barbalias GA. Risk factors for tuberculosis in dialysis patients: a prospective multi-center clinical trial. BMC Nephrol 2009;10:36.
Footnote 48
Hadzibegovic DS, Maloney SA, Cookson S, Oladele A. Determining TB rates and TB case burden for refugees. Int J Tuberc Lung Dis 2005;9(4):409-14.
Footnote 49
Cain KP, Benoit SR, Mac Kenzie WR. Tuberculosis  among foreign-born persons in the United States. JAMA 2008;300(4):405.
Footnote 50
Public Health Agency of Canada. Report from National Diabetes Surveillance System. Diabetes in Canada 2008. Ottawa: PHAC, 2008.
Footnote 51
Creatore MI, Moineddin R, Booth G, et al. Age- and sex-related prevalence of diabetes mellitus among immigrants to Ontario, Canada. CMAJ 2010;182(8):781-789.
Footnote 52
Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLOS Med 2008;5(7):e152.
Footnote 53
Baker MA, Harris AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 2011;9:81.
Footnote 54
Kamboj M, Sepkowitz K. The risk of tuberculosis in patientss with cancer. Clin Infect Dis 2006;42(11):1592-95.
Footnote 55
Feld 1, Kaplan MH, Armstrong D, Rosen P. Tuberculosis complicating neoplastic disease.  A review of 201 cases. Cancer 1974;33(3):850-58. Feld+1,+Kaplan+MH,+Armstrong+D,+Rosen+P.+Tuberculosis+complicating+neoplastic+disease.++A+review+
Footnote 56
Feld R, Bodey GP, Groschel D. Mycobacteriosis in patients with malingnant disease. Arch Intern Med 1976;136(1):67-70.
Footnote 57
Rehm J, Samokhvalov AV, Neuman MG, et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB): a systematic review. BMC Public Health 2009;9:450.
Footnote 58
Lonnroth K, Castro G, Chakaya JM, et al. Tuberculosis control and elimination 2010-50: cure, care and social development. Lancet 2010;375(9728):1814-29.
Footnote 59
Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010;(1):CD000171.
Footnote 60
Samandari T, Agizew TB, Nyirenda S, et al. A randomized placebo-controlled trial of 6 versus 36 months isoniazid tuberculosis preventive therapy for HIV-infected adults in Botswana. Lancet 2011;377:1588-98.
Footnote 61
Gordin FM, Matts JP, Miller C, Brown LS, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997;337(5):315-20.
Footnote 62
Fitzgerald DW, Severe P, Joseph P, Mellon LR, Johnson WD, Pape JW. No effect of isoniazid prophylaxis for PPD-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. J Acquir Immune Defic Syndr 2001;28:305-307.
Footnote 63
International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull Wld Hlth Org 1982;60(4):555-64.
Footnote 64
Gordin FM, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons. JAMA 2000;283(11):1445-50.
Footnote 65
Mohammad A, Myer L, Ehrlich R, Wood R, Cilliers G, Maartens G. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease. Int J Tuber Lung Dis 2007;11(10):1114.
Footnote 66
Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-72.
Footnote 67
Alfaro EM, Serna E, Solera J, et al. Compliance, tolerance and efficacy of a short course of chemoprophylaxis for tuberculosis. Med Clin (Barc) 98;111:4014.
Footnote 68
Menzies D, Long R, Trajman A, et al. Adverse events with 4 months rifampin or 9 months isoniazid as therapy for latent TB infection: results of a randomized trial. Ann Intern Med 2008;149:689-97.
Footnote 69
Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifampin and isoniazid for latent tunerculosis injection. N Engl J Med 2011;365(23).
Footnote 70
Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4- month regimens of isoniazid plus rifampin for Treatment of Latent Tuberculosis Infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715.
Footnote 71
Comstock GW. How much isoniazid is needed for prevention of tuberculosis in immunocompetent adults? Int J Tuberc Lung Dis 1999;3(10):847-50.
Footnote 72
Rivero A, Lopez-Cortes L, Castillo R, et al. Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy. Enferm Infecc Microbiol Clin 2003;21(6):287-92. Rivero+A,+Lopez-Cortes+L,+Castillo+R,+et+al.+Randomized+trial+of+three+regimens+to+prevent+tuberculosis+in+HIV-infected+patients+with+anergy.+Enferm+Infecc+Microbiol+Clin+2003;21(6)%3A287-92.&report=abstract
Footnote 73
Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997;337(12):801-808.
Footnote 74
Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tunberculosis in adults with HIV infection. N Engl J Med 2011;365(1):11-20.
Footnote 75
Halsey NA, Coberly JS, Desormeaux J, et al. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786-92.
Footnote 76
Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998;12:2447-57.
Footnote 77
Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004;170(4):445-49.
Footnote 78
Alfaro EM, Cuadra F, Solera J, et al. Assessment of two chemoprophylaxis regimens for tuberculosis in HIV-infected patients. Med Clin (Barc) 2000;115:161-5.
Footnote 79
Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006;173(8):922-26.
Footnote 80
Gray DM, Zar H, Cotton M. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. Cochrane Database Syst Rev 2009;(1):CD006418.
Footnote 81
Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000;(2):CD001363.
Footnote 82
Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005;40(5):670-76.
Footnote 83
Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006;166(17):1863-70.
Footnote 84
Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006;130:1712.
Footnote 85
Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventative therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-93.
Footnote 86
Medinger A. Death associated with rifampin and pyrazinamide 2-month treatment of latent Mycobacterium tuberculosis. Chest 2002;121:1710-12.
Footnote 87
Centers for Disease Control. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection - New York and Georgia, 2000. Morb Mortal Wkly Rep 2001;50(15):289-91.
Footnote 88
American Thoracic Society, Centers for Disease Control. Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in the American Thoracic Society/CDC recommendations. Morb Mortal Wkly Rep 2001;50(34):733-35.
Footnote 89
American Thoracic Society, Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for Treatment of Latent Tuberculosis Infection - United States, 2003. Morb Mortal Wkly Rep 2003;52(31):735-39.
Footnote 90
Zar HJ, Cotton MF, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children HIV: randomised contolled trial. Brit Med J 2007;334:136.
Footnote 91
McNab BD, Marciniuk DD, Alvi RA, Tan L, Hoeppner VH. Twice weekly isoniazid and rifampin Treatment of Latent Tuberculosis Infection in Canadian plains Aborigines. Am J Respir Crit Care Med 2000;162:989-93.
Footnote 92
Garibaldi RA, Drustin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis. Am Rev Respir Dis 1972;106:357-65.
Footnote 93
Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis. Am Rev Respir Dis 1978;117:991-1001.
Footnote 94
SalpeterSR. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med 1993;159:560-64.
Footnote 95
Smith BM, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. Can Med Assoc J 2011;183(3):E173.
Footnote 96
Devrim I, Olukman O, Can D, Dizdarer C, Turkey I. Risk factors for isoniazid hepatotoxicity in children with latent TB and TB: difference from adults. Chest 2010;137(3):737-38.
Footnote 97
Wu Ss, Chao CS, Vargas JH, et al. Isoniazid-related hepatic failure in children: a survey of liver transplant centers. Transplantation 2007;84(2):173-79.
Footnote 98
Palusci VJ, O'Hare D, Lawrence RW. Hepatotoxicity and transaminase measurement during isoniazid chemoprohylaxis in children. Pediatr Infect Dis J 1995;14(2):144-48.
Footnote 99
Nakajo MM, Roa M, Steiner P. Incidence of hepatotoxicity in children receiving isonaizid chemoprophylaxis. Pediatr Infect Dis J 1989;8(9):649-50.
Footnote 100
Spyrisis P, Sinaniotis C, Papadea I, Oreopoulos L, Hadjiyiannis S, Papadatos C. Isoniazid liver injury during chemoprophylaxis in children. Arch Dis Child 1979;54(1):65-7.
Footnote 101
Litt IF, Cohen MI, McNamara H. Isoniazid hepatitis in adolescents. J Pediatr 1976;89(1):133-35.
Footnote 102
Beaudry PH, Brickman HF, Wise MB, MacDonald D. Liver enzyme disturbance during isoniazid chemoprophylaxis in children. Am Rev Respir Dis 1974;110(5):581-84.
Footnote 103
Hsu KH. Isoniazid in the prevention and treatment of tuberculosis. A 20-year study of the effectiveness in children. JAMA 1974;229(5):528-33.
Footnote 104
Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with Treatment of Latent Tuberculosis Infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005;128(1):116-23.
Footnote 105
Nolan CM, Goldberg SV, Buskin SE. Hepatoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281(11):1014-18.
Footnote 106
LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003;168:443-47.
Footnote 107
Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Engl J Med 1985;23:1483-87.
Footnote 108
Stead WW, To T, Harrison RW, Abraham JH. Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med 1987;107:843-45.
Footnote 109
Franks A, Binkin NJ, Snider DE, Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum hispanic patients. Public Health Rep 1989;104(2):151-55.
Footnote 110
Snider DE, Powell KE. Should women taking antituberculosis drugs breast-feed? Arch Intern Med 1984;144:589-90.
Footnote 111
Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato IM. Asymptomatic hepatitis in persons who received alternative preventative therapy with pyrazinamide and ofloxacin. Clin Infect Dis 1997;24:1264-65.
Footnote 112
Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multi-drug-resistant tuberculosis. Can Med Assoc J 2002;167:131-36.
Footnote 113
Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180(3):273-80.
Footnote 114
Paterson JM, Mamdani MM, Manno M, Juurlink DN, the Canadian Drug Safety and Effectiveness Research Network. Fluoroquinolone therapy and idiosyncratic acute liver injury:a population-based study. Can Med Assoc J 2012;184(14):1565-70.
Footnote 115
Sumartojo E. When tuberculosis treatment fails:  a social behavioural account of patient adherence. Am Rev Resp Dis 1993;147:1311-20.
Footnote 116
Besch CL. Compliance in clinical trials. AIDS 1995;9(1):1-10.
Footnote 117
Mason BJ, Matsuyama JR, Jue SG. Assessment of sulfonylurea adherence and metabolic control. Diabetes Educ 1995;21(1):52-7.
Footnote 118
Moulding TS, Redeker AG, Kanel GC. Twenty isoniazid associated deaths in one state. Am Rev Resp Dis 1989;140:700-705.
Footnote 119
Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159(1):15-21.
Footnote 120
Menzies D. Issues in the management of contacts of patients with active pulmonary tuberculosis. Can J Public Health 1997;88(3):197-201.
Footnote 121
Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006;12(5):744-51.
Footnote 122
Nolan CM, Aitken ML, Elarth AM, Anderson KM, Miller WT. Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. Am Rev Respir Dis 1986;133:431-36.

[Previous page] [Table of Contents] [Next page]